---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-24-000055"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:23:07.665949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY

## Summary
- Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.
- Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.
- Cash, equivalents, and investments of $232.9M as of June 30, 2024.
- Expense increase driven by higher headcount to support product development.
- Company continues development of single-molecule proteome analysis platform.

## SEC filing metadata
- accession: 0001808805-24-000055
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/0001808805-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/naut-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-24-000055
- JSON: https://secwatch.observer/filing/0001808805-24-000055.json
- Plain text: https://secwatch.observer/filing/0001808805-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.